https://clinicaltrials.gov/ct2/show/NCT02422979 This study is currently recruiting participants. (see Contacts and Locations) Verified November 2016 by Aspyrian Therapeutics, Inc. This is a Phase 1, two part, study of patients with recurrent Head and Neck Cancer (HNC),
Part II is a light treatment dose-escalation, fixed drug dosing infusion study to determine the optimal light application, in combination with the Part I drug dose, needed to achieve clinical response with an acceptable safety profile.